Pancreatic Cancer Research

ResearcherKyoto Prefectural University of MedicineActive in the last 2 years

Taisuke Imamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5128-6550; OpenAlex author ID A5071081581. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 16

  1. Rising Pancreatic Cancer Incidence in Young Japanese Women and Increasing Distal Pancreatectomy in Older Adults: A Nationwide Claims-Based Analysis From 2016 t… Co-author DOI 10.1002/ags3.70178↗
  2. [Resection of Borderline Resectable Pancreatic Cancer with Arterial Involvement Following a Marked Response to Neoadjuvant Chemotherapy-A Case Report]. Co-author PMID 42723240↗
  3. Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. Co-author DOI 10.1093/bjs/znae059↗
  4. Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma. Co-author DOI 10.1186/s12885-024-12676-x↗
  5. Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. Co-author DOI 10.1002/ags3.12636↗
  6. Characterization of pancreatic cancer with ultra-low tumor mutational burden. Co-author DOI 10.1038/s41598-023-31579-8↗
  7. The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Co-author DOI 10.1016/j.pan.2022.03.017↗
  8. Histological Differentiation Is a Pivotal Prognostic Factor Associated With the Pattern of Recurrence Following Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001848↗
  9. Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09066-5↗
  10. Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-09593-9↗
  11. ASO Author Reflections: Albumin-Bilirubin Grade is an Independent Prognostic Factor Complementary to CA19-9 for Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-021-09660-1↗
  12. Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00423-020-01970-4↗
  13. Prognostic role of the length of tumour-vein contact at the portal-superior mesenteric vein in patients having surgery for pancreatic cancer. Co-author DOI 10.1002/bjs.11328↗
  14. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Co-author DOI 10.1038/s41598-017-06137-8↗
  15. Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. Co-author DOI 10.3748/wjg.v22.i25.5627↗
  16. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Co-author DOI 10.1038/bjc.2015.366↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teiichi Sugiura · 10 shared papers, 2019–2024 · strength 1.40
  2. Ryo Ashida · 10 shared papers, 2019–2024 · strength 1.40
  3. Katsuhiko Uesaka · 10 shared papers, 2019–2024 · strength 1.40
  4. Katsuhisa Ohgi · 10 shared papers, 2019–2024 · strength 1.40
  5. Yukiyasu Okamura · 9 shared papers, 2019–2024 · strength 1.25
  6. Atsushi Shiozaki · 6 shared papers, 2015–2026 · strength 0.86
  7. Takaaki Ito · 6 shared papers, 2019–2022 · strength 0.75
  8. Ryo Morimura · 5 shared papers, 2015–2026 · strength 0.67
  9. Keiichi Ohshima · 3 shared papers, 2023–2024 · strength 0.52
  10. Hidemasa Kubo · 2 shared papers, 2026 · strength 0.52
  11. Yusuke Yamamoto · 3 shared papers, 2021–2024 · strength 0.46
  12. Eigo Otsuji · 4 shared papers, 2015–2024 · strength 0.34
  13. Mihoko Yamada · 2 shared papers, 2023–2024 · strength 0.34
  14. Kenichi Urakami · 2 shared papers, 2023–2024 · strength 0.34
  15. Ken Yamaguchi · 2 shared papers, 2023 · strength 0.33
  16. Masamitsu Kido · 1 shared paper, 2026 · strength 0.28
  17. Goshi Takayama · 1 shared paper, 2026 · strength 0.24
  18. Akira Fukutomi · 2 shared papers, 2019–2020 · strength 0.19
  19. Akiko Todaka · 2 shared papers, 2019–2020 · strength 0.19
  20. Ken D Yamaguchi · 1 shared paper, 2024 · strength 0.18
  21. Shunsuke Tamura · 1 shared paper, 2022 · strength 0.15
  22. Mahito Miyamae · 3 shared papers, 2015–2017 · strength 0.15
  23. Daisuke Ichikawa · 3 shared papers, 2015–2017 · strength 0.15
  24. Tsutomu Kawaguchi · 2 shared papers, 2015–2016 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.